Hainan Poly Pharm. Co., Ltd

300630

CNE100002N10

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
14.67 ^CNY	+0.96%		+1.10%	-35.15%

Apr. 08	Hainan Poly Pharm Gets Nod to Market Voriconazole Injection in Sweden	MT
Apr. 04	Hainan Poly Pharm Gets Nod to Market Skin Infection Drug in Germany	MT

Hainan Poly Pharm. Co., Ltd. Approves Profit Distribution Proposal for 2020

May 19, 2021 at 03:38 pm EDT

Hainan Poly Pharm. Co., Ltd., at its AGM held on May 18, 2021, approved profit distribution proposal of CNY 1.87 per 10 shares (tax included) for the year 2020.

Latest news about Hainan Poly Pharm. Co., Ltd

Hainan Poly Pharm Gets Nod to Market Voriconazole Injection in Sweden	Apr. 08	MT
Hainan Poly Pharm Gets Nod to Market Skin Infection Drug in Germany	Apr. 04	MT
Hainan Poly Pharm's Brivaracetam Injection Gets FDA's Nod to Enter US Market; Shares Up 3%	Mar. 04	MT
Hainan Poly Pharm's Epilepsy Drug Gets FDA's Greenlight to Enter US Market	Feb. 19	MT
Hainan Poly Pharm to Apply For Up to 3.8 Billion Yuan Credit Line	Jan. 11	MT
Hainan Poly Pharm Gets Nod to Market Pantoprazole Sodium for Injection in Singapore	Dec. 12	MT
Hainan Poly Pharm. Co., Ltd(SZSE:300630) dropped from Shenzhen Stock Exchange Component A Share Index	Dec. 11	CI
Hainan Poly Pharm. Co., Ltd(SZSE:300630) dropped from Shenzhen Stock Exchange Component Index	Dec. 11	CI
Hainan Poly Pharm. Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-24	CI
Hainan Poly Pharm's Gets US FDA Nod to Market Iopamidol Injection	23-10-09	MT
Hainan Poly Pharm Gets Approval to Market Fluconazole Dry Suspension in US	23-09-25	MT
Tranche Update on Hainan Poly Pharm. Co., Ltd's Equity Buyback Plan announced on April 25, 2023.	23-09-15	CI
Hainan Poly Pharm. Co., Ltd's Equity Buyback announced on April 25, 2023 has closed with 1,426,700 shares, representing 0.33% for CNY 30.03 million.	23-09-13	CI
Hainan Poly Pharm's Unit Passes US FDA's On-Site Inspection	23-09-11	MT
Hainan Poly Pharm. Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Hainan Poly Pharm's Unit Passes Regulator's GMP Inspection	23-08-07	MT
Hainan Poly Pharm Wins FDA Nod to Market Azithromycin Variant in US	23-07-31	MT
Hainan Poly Pharm. Co., Ltd Announces Dividend Implementation of Cash Dividend for 2022, Payable on 18 July 2023	23-07-11	CI
Tranche Update on Hainan Poly Pharm. Co., Ltd's Equity Buyback Plan announced on April 25, 2023.	23-07-03	CI
Hainan Poly Pharm. Co.,Ltd Approves Cash Dividend for 2022	23-05-24	CI
Hainan Poly Pharm Gets Regulatory OK to Convert Desloratadine Dispersible Tablets into Over-The-Counter Drugs	23-05-04	MT
Hainan Poly Pharm. Co.,Ltd Proposes Final Profit Distribution for 2022	23-04-25	CI
Hainan Poly Pharm. Co., Ltd announces an Equity Buyback for CNY 60 million worth of its shares.	23-04-24	CI
Hainan Poly Pharm. Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
Hainan Poly Pharm. Co., Ltd authorizes a Buyback Plan.	23-04-22	CI

Chart Hainan Poly Pharm. Co., Ltd

Duration

Period

More charts

Hainan Poly Pharm Co Ltd is a company engaged in research and development, production and sales of drugs. The Company operates five segments. The Anti-Allergic segment is engaged in the production of desloratadine dispersible tablets, desloratadine dry suspension and desloratadine tablets. The Antibiotic segment provides levofloxacin hydrochloride capsules and azithromycin dry suspension for the treatment of bacterial infections. The Nonsteroidal Anti-inflammatory Drugs segment provides diclofenac sodium enteric-coated sustained-release capsule products for the treatment of arthritis and dysmenorrhea. The Digestive segment is involved in providing trimebutine maleate tablets to treat abdominal pain, diarrhea, and irritable bowel syndrome. The Company also operates Other segment.

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Hainan Poly Pharm. Co., Ltd

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.67

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HAINAN POLY PHARM. CO., LTD	-35.15%	900M
ELI LILLY AND COMPANY	+25.83%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.76%	354B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+3.00%	296B
ASTRAZENECA PLC	+13.09%	233B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-6.26%	144B

Other Pharmaceuticals